Evidence map›Paper›PMID 37809945›Full record

ArticleHeliyon2023

Gelatin-coated silicon oxide nanoparticles encapsulated recombinant human secretory leukocyte protease inhibitor (rhSLPI) reduced cardiac cell death against an

Faprathan Pikwong, Chayanisa Phutiyothin, Wannapat Chouyratchakarn, Phornsawat Baipaywad, Podsawee Mongkolpathumrat, Sarawut Kumphune

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Faprathan PikwongBiomedical Engineering Institute (BMEI), Chiang Mai University, Mueang Chiang Mai District, Chiang Mai, 50200 Thailand.
Chayanisa PhutiyothinBiomedical Engineering Institute (BMEI), Chiang Mai University, Mueang Chiang Mai District, Chiang Mai, 50200 Thailand.
Wannapat ChouyratchakarnBiomedical Engineering Institute (BMEI), Chiang Mai University, Mueang Chiang Mai District, Chiang Mai, 50200 Thailand.
Phornsawat BaipaywadBiomedical Engineering Institute (BMEI), Chiang Mai University, Mueang Chiang Mai District, Chiang Mai, 50200 Thailand.
Podsawee MongkolpathumratCardio-Thoracic Technology program, Chulabhorn International College of Medicine, Thammasat University (Rangsit Center), Cooperative Learning Center, Piyachart 2, 99 Moo 18 Klong Luang, Rangsit, Pathumthani 12120, Thailand.
Sarawut KumphuneBiomedical Engineering Institute (BMEI), Chiang Mai University, Mueang Chiang Mai District, Chiang Mai, 50200 Thailand.
Chiang Mai University · THThammasat University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic Heart Disease (IHD) is the main global cause of death. Previous studies indicated that recombinant human secretory leukocyte protease inhibitor (rhSLPI) exhibits a cardioprotective effect against myocardial ischaemia/reperfusion (I/R) injury. However, SLPI has a short half-life

Indexed as

Gelatin-covered silica nanoparticlesIschaemia and reperfusion (I/R) injuryNanoparticlesSecretory leukocyte protease inhibitor (SLPI)

Identifiers

PMID37809945
PMCPMC10559932
OpenAlexW4386799453

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.